Barouyr Baroudjian is an expert in Oncology at Assistance Publique - Hôpitaux de Paris (France). Barouyr Baroudjian has authored 190 publications, the most recent in 2025, and is an investigator in 3 clinical trials. SLR score: 464 (community average: 125). How the SLR is computed.

LeadR Profile

464 ScienceLeadR Reputation 464
Network Map

Oncology

Subspecialties: Dermatology - Neurology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2014 - 2026

Source: PubMed

Hôpital Saint-Louis

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Primary Sweat Gland Adenocarcinoma of the Skin With ATL2::PRKD3 Fusion: A Potential Cutaneous Analog of Cribriform Adenocarcinoma of the Salivary Glands?
PMID 41225782 — skin, cell transformation, neoplastic, salivary glands, neoplasms, adenocarcinoma, chromosome aberrations, sweat glands
Genes Chromosomes Cancer20250
Impact of reflectance confocal microscopy on surgical outcomes in lentigo maligna and lentigo maligna melanoma: A retrospective cohort study of 282 patients.
PMID 41066870 — microscopy, confocal, melanoma, hutchinson's melanotic freckle, cohort studies, microscopy, lentigo
J Plast Reconstr Aesthet Surg20250
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
PMID 40658732 — syphilis, melanoma, drug-related side effects and adverse reactions, immune checkpoint inhibitors, therapeutics, dermatology
Br J Dermatol20253
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.
PMID 40449497 — progression-free survival, melanoma, neoplasms, drug-related side effects and adverse reactions, immune checkpoint inhibitors, nivolumab, therapeutics, ipilimumab, mutation
Lancet Oncol Top journal20257
Immune checkpoint inhibitors induced subcutaneous panniculitis-like T-cell lymphoma.
PMID 40334433 — cells, sexually transmitted diseases, lymphoma, immune checkpoint inhibitors, t-lymphocytes, panniculitis, dermatology, lymphoma, t-cell
Ann Dermatol Venereol20250

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 1/Phase 2 1
Phase 2 1

By status:

Active not recruiting 1
Recruiting 1
Unknown 1

By type:

Interventional 2
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 2

Main Topics

LeadR Networks

Main global connection map